Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice

Dafna D Gladman; Yves Poulin; Karen Adams; Marc Bourcier; Snezana Barac; Kirk Barber; Vinod Chandran; Jan Dutz; Cathy Flanagan; Melinda J Gooderham; Wayne P Gulliver; Vincent C Ho; Chih-Ho Hong; Jacob Karsh; Majed M Khraishi; Charles W Lynde; Kim A Papp; Proton Rahman; Sherry Rohekar; Cheryl F Rosen; Anthony S Russell; Ronald B Vender; Jensen Yeung; Olga Ziouzina; Michel Zummer

doi:10.3899/jrheum.161473

Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice

J Rheumatol. 2017 Apr;44(4):519-534. doi: 10.3899/jrheum.161473.

Authors

Dafna D Gladman^{1

2}, Yves Poulin^{3

4}, Karen Adams^{3

4}, Marc Bourcier^{3

4}, Snezana Barac^{3

4}, Kirk Barber^{3

4}, Vinod Chandran^{3

4}, Jan Dutz^{3

4}, Cathy Flanagan^{3

4}, Melinda J Gooderham^{3

4}, Wayne P Gulliver^{3

4}, Vincent C Ho^{3

4}, Chih-Ho Hong^{3

4}, Jacob Karsh^{3

4}, Majed M Khraishi^{3

4}, Charles W Lynde^{3

4}, Kim A Papp^{3

4}, Proton Rahman^{3

4}, Sherry Rohekar^{3

4}, Cheryl F Rosen^{3

4}, Anthony S Russell^{3

4}, Ronald B Vender^{3

4}, Jensen Yeung^{3

4}, Olga Ziouzina^{3

4}, Michel Zummer^{3

4}

Affiliations

¹ From the University of Toronto, Toronto, Ontario; Université Laval, Quebec, Quebec; Queen's University, Kingston; University of Ottawa, Ottawa; Western University, London; Dermatrials Research, Inc., Hamilton, Ontario; Université de Montréal, Montreal; Université de Sherbrooke, Sherbrooke, Quebec; The Winnipeg Clinic, Winnipeg, Manitoba; University of Calgary, Calgary; University of Alberta, Edmonton, Alberta; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland, Canada. dafna.gladman@utoronto.ca.
² D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto; Y. Poulin, MD, Université Laval; K. Adams, MD, Université Laval; M. Bourcier, MD, Université de Sherbrooke; S. Barac, MD, The Winnipeg Clinic; K. Barber, MD, University of Calgary; V. Chandran, MBBS, MD, DM, PhD, University of Toronto; J. Dutz, MD, University of British Columbia; C. Flanagan, MD, University of British Columbia; M.J. Gooderham, MD, Queen's University; W.P. Gulliver, MD, Memorial University of Newfoundland; V.C. Ho, MD, University of British Columbia; C.H. Hong, MD, University of British Columbia; J. Karsh, MD, University of Ottawa; M.M. Khraishi, MBBCH, Memorial University of Newfoundland; C.W. Lynde, MD, University of Toronto; K.A. Papp, MD, PhD, University of Toronto; P. Rahman, MD, Memorial University of Newfoundland; S. Rohekar, MD, Western University; C.F. Rosen, MD, University of Toronto; A.S. Russell, MD, University of Alberta; R.B. Vender, MD, Dermatrials Research, Inc.; J. Yeung, MD, University of Toronto; O. Ziouzina, MD, University of Calgary; M. Zummer, MD, Université de Montréal. dafna.gladman@utoronto.ca.
³ From the University of Toronto, Toronto, Ontario; Université Laval, Quebec, Quebec; Queen's University, Kingston; University of Ottawa, Ottawa; Western University, London; Dermatrials Research, Inc., Hamilton, Ontario; Université de Montréal, Montreal; Université de Sherbrooke, Sherbrooke, Quebec; The Winnipeg Clinic, Winnipeg, Manitoba; University of Calgary, Calgary; University of Alberta, Edmonton, Alberta; University of British Columbia, Vancouver, British Columbia; Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
⁴ D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto; Y. Poulin, MD, Université Laval; K. Adams, MD, Université Laval; M. Bourcier, MD, Université de Sherbrooke; S. Barac, MD, The Winnipeg Clinic; K. Barber, MD, University of Calgary; V. Chandran, MBBS, MD, DM, PhD, University of Toronto; J. Dutz, MD, University of British Columbia; C. Flanagan, MD, University of British Columbia; M.J. Gooderham, MD, Queen's University; W.P. Gulliver, MD, Memorial University of Newfoundland; V.C. Ho, MD, University of British Columbia; C.H. Hong, MD, University of British Columbia; J. Karsh, MD, University of Ottawa; M.M. Khraishi, MBBCH, Memorial University of Newfoundland; C.W. Lynde, MD, University of Toronto; K.A. Papp, MD, PhD, University of Toronto; P. Rahman, MD, Memorial University of Newfoundland; S. Rohekar, MD, Western University; C.F. Rosen, MD, University of Toronto; A.S. Russell, MD, University of Alberta; R.B. Vender, MD, Dermatrials Research, Inc.; J. Yeung, MD, University of Toronto; O. Ziouzina, MD, University of Calgary; M. Zummer, MD, Université de Montréal.

PMID: 28604347
DOI: 10.3899/jrheum.161473

Abstract

Objective: To develop preliminary treat-to-target (T2T) recommendations for psoriasis and psoriatic arthritis (PsA) for Canadian daily practice.

Methods: A task force composed of expert Canadian dermatologists and rheumatologists performed a needs assessment among Canadian clinicians treating these diseases as well as an extensive literature search on the outcome measures used in clinical trials and practice.

Results: Based on results from the needs assessment and literature search, the task force established 5 overarching principles and developed 8 preliminary T2T recommendations.

Conclusion: The proposed recommendations should improve management of psoriasis and PsA in Canadian daily practice. However, these recommendations must be further validated in a real-world observational study to ensure that their use leads to better longterm outcomes.

Keywords: ASSESSMENT; PSORIASIS; PSORIATIC ARTHRITIS; TREAT-TO-TARGET.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Psoriatic / drug therapy*
Canada
Disease Management
Humans
Psoriasis / drug therapy*
Quality of Health Care*